Jaguar Health (JAGX) Receiving Favorable Press Coverage, Study Shows

Headlines about Jaguar Health (NASDAQ:JAGX) have been trending positive on Friday, Accern reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Jaguar Health earned a news sentiment score of 0.39 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 44.6962973148988 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news articles that may have effected Accern’s analysis:

Jaguar Health (NASDAQ JAGX) remained flat at $$0.13 on Friday. The company had a trading volume of 820,250 shares, compared to its average volume of 2,022,413. The stock has a market cap of $12.33, a price-to-earnings ratio of -0.20 and a beta of 0.41. Jaguar Health has a fifty-two week low of $0.10 and a fifty-two week high of $1.52. The company has a current ratio of 0.26, a quick ratio of 0.15 and a debt-to-equity ratio of 0.35.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://transcriptdaily.com/2018/01/05/jaguar-health-jagx-receiving-favorable-press-coverage-study-shows.html.

Jaguar Health Company Profile

Jaguar Health, Inc, formerly Jaguar Animal Health, Inc, is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc, is focused on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

Insider Buying and Selling by Quarter for Jaguar Health (NASDAQ:JAGX)

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply